Associated Papers
Bioinformatics Approach to mTOR Signaling Pathway-Associated Genes and Cancer Etiopathogenesis.
Ozdilli K et al.
Genes, 2025
mTOR Variants Activation Discovers PI3K-like Cryptic Pocket, Expanding Allosteric, Mutant-Selective Inhibitor Designs.
Liu Y et al.
Journal of Chemical Information and Modeling, 2025
39792006 (PubMed )
Supplement: ci4c02022_si_002.xlsx › Sheet1
Ovarian germ cell tumor/mastocytosis with KIT mutation: A unique clinicopathological entity.
Xiao P et al.
Genes, Chromosomes & Cancer, 2022
mTOR: Role in cancer, metastasis and drug resistance.
Murugan AK
Seminars in Cancer Biology, 2019
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.
Clark DJ et al.
Cell, 2019
31675502 (PubMed )
Supplement: NIHMS1597713-supplement-Table_S7.xlsx › NeoFlow
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
Xu J et al.
The Journal of Clinical Investigation, 2016
Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer.
Yamaguchi H et al.
Cancer Science, 2015
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP et al.
Oncotarget, 2015
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
Grabiner BC et al.
Cancer Discovery, 2014
Clonal architectures and driver mutations in metastatic melanomas.
Ding L et al.
Plos One, 2014
25393105 (PubMed )
Supplement: pone.0111153.s002.zip › File_S2 › Table_S10.xls › Supp_Table_10
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.
Varela I et al.
Nature, 2011
21248752 (PubMed )
Supplement: NIHMS33194-supplement-1.pdf
Select a paper to view details